BESTMSLs, a Uniphar company’s Post

🧬ATMPs are highly innovative technologies developed as a result of a long, complex and often difficult research, development and market access process. 👩🔬As these transformative therapies come to the European market in greater numbers, and as their importance to the competitiveness of the Single Market is becoming increasingly apparent, we put together a short but comprehensive guide to the ATMP lifecycle, zeroing in on the complex processes and most significant hurdles developers must navigate at each stage of the cycle. 🔬Click here to find out what it takes to bring ATMPs to the lives of European patients: https://lnkd.in/eKhrXqwF #ATMPs #cellandgenetherapy #orphandrug #innovation

Thank you to Albert Rønning-Andersson and MedWatch for this article on Lophora. To summarize for non-Danish speaking, non-Medwatch subscribers: GROWING APPETITE FOR PSYCHEDELICS WILL ENSURE PHASE 1-READY BIOTECH A SALE OR PARTNERSHIP: "WE ARE IN THE MIDDLE OF A PSYCHEDELIC RENAISSANCE" Submitting the CTA is a major accomplishment and milestone for Lophora, given that we are a small team with limited resources. If all goes as expected, we believe a near-term exit is a highly likely scenario. Lophora is in the midst of raising a small financing round of DKK20M and in parallel are in discussions with several potential partners (from big pharma to big psychedelic). Our primary aim is to is to execute and complete our Phase I, then subsequently select the right partner for LPH-5 to give it the best chance of reaching patients in need. https://lnkd.in/ehfS3_Qe #clinicaltrialauthorization #cta #phase1 #clinicaldevelopment #psychedelicresearch #psychedelics #nextgeneration #biotech #hope #BioInnovationInstitute #DKBiotek #neuroscience #CNS

K-binders hold great promise in transforming the optimization of RAASi treatment in HFrEF. However, while these drugs are highly effective, it is crucial to overcome clinical inertia and the fear of hyperkalemia, especially considering that up to 50% of patients at risk never actually develop it! Our perspective on K-binders, exploring insights from the recently published REALIZE-K trial in #HeartFailureReviews: https://rdcu.be/d77jP INI CRCT CHRU de Nancy CIC Plurithématique Universite de Lorraine Nicolas GIRERD Patrick Rossignol Francesca Musella

"We are stronger - Together", that has been Medicon Valley Alliance motto for decades. And we have walked that talk. With 350+ life science members in our Danish-Swedish Medicon Valley comprising of the hospitals in the region, the universities and hundreds of private life science companies, we have created a cross-border eco-system of world class researchers, clinicians and other life science talent - a region with a talent pool of 75,000+ professionals working in life science today and continually expanding. Home to hundreds of R&D facilities, Medicon Valley, as highlighted in our recent "State of Medicon Valley" report (link in comment), ranks second in Europe for manufacturing facilities and leads in #CDMO facilities 💪 But on the global scale, we are still small nations and need all the peers, we can get in order to compete with the States and Asia. We need to strengthen our competitiveness in Europe - and even though, we are thrilled that the European Commission mentions Medicon Valley Alliance in Draghi's report on the "Future of European Competitiveness", Europe is loosing ground. So, I totally agree with Andreas Muranyi Scheutz - we are not each others competitors in the Nordics - and we should be better at joining forces and utilitize our like-mindedness to make us stronger whether that's in the EU or globally. At Medicon Valley Alliance we look forward to a closer collaboration with Region Stockholm and their new Stockholm-Uppsala life science cluster region. Niels Abel Bonde Matthew Iles Pontus Holm Citeline Jean-Marc Mezin

The FDA "Final Rule" is now in effect -- are you ready? On Thursday, September 26, the Association for Academic Pathology (AAPath) will be hosting a webinar on some laboratory developed testing examples. Myself and our very own coagulation director, Dr. David Unold, will be presenting on the: "Best Case and Worst Case Scenarios: Practical Approaches to the FDA’s LDT Final Rule". This is a third in a series for laboratory professionals to address these new FDA regulations.

Collaborative innovations starts with great partnerships.

🚀 Exciting Breakthrough in Biotech! 🚀 Cilcare, a trailblazer in hearing-loss therapies, has closed a €40M Series A funding round! This major milestone will propel their cutting-edge work on solutions for sensorineural hearing loss, including the advancement of CIL001, their innovative drug tackling cochlear synaptopathy. 🧬👂 With this investment, Cilcare is set to transform the future of auditory health, addressing the needs of millions worldwide. A huge congratulations to their team for pushing boundaries in science and innovation! 🙌 🔗 Read more here: https://lnkd.in/eP4sTeiJ #Biotech #HealthcareInnovation #HearingHealth #Cilcare #LifeSciences #SeriesA #MedTech

If you attended #DIA2024 and find yourself in a post-conference slump, I've got exciting news for you! Among the sponsors at DIA, more than 30 companies have announced plans to start phase 2 or phase 3 trials since last month. For instance, Tyra Bio, a company with just over 50 employees, is gearing up for a Phase 2 study in pediatric achondroplasia. They've already secured significant funding in 2024. Don't let important opportunities slip through the cracks after conferences! Connect with me at [email protected] or DM me to discuss how we can help you achieve your conference ROI and make your sales teams more proactive. #conferences #sponsors #clinicaltrials

Lipum to participate in the following upcoming events and meetings: NLSDays | 18-19 September | Malmö BioEurope | 4-6 November | Stockholm Redeye Autoinflammatory day | 20 November | Stockholm BioStockSummit | 20-21 November| Lund "These meetings provide a good opportunity for us to present and discuss our progress and results from our first clinical phase 1 study, to share our ongoing plans as well as presenting key milestones and triggers with investors and partners" says CEO Ola Sandborgh. #lipum #investorrelations #lifescience